Loading...
•
Mar 31, 2022
Curis Q1 2022 Earnings Report
Curis reported a net loss and advanced clinical trials of emavusertib in Q1 2022.
Key Takeaways
Curis reported a net loss of $16.1 million, or $0.18 per share, for the first quarter of 2022. Revenues were $2.1 million, primarily from royalty revenues. The company's cash, cash equivalents, and investments totaled $120.7 million as of March 31, 2022, expected to fund operations into 2024. Two TakeAim studies were put on partial clinical hold by the FDA.
Advanced clinical trials of emavusertib across nine patient populations.
Reported preliminary data showing early anti-cancer activity of emavusertib in AML/MDS patients.
Presented initial data from the dose escalation study of CI-8993 in patients with relapsed/refractory solid tumors.
TakeAim studies were put on partial clinical hold by the FDA.
Revenue by Segment
Forward Guidance
Curis anticipates presenting data from the TakeAim Lymphoma and Leukemia studies, along with updates from the CI-8993 study throughout 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...